Mucopolysaccharidosis (MPS) type IIIA, or Sanfilippo syndrome, is a neurodegenerative lysosomal storage disorder caused by a deficiency of the lysosomal enzyme N-sulfoglucosamine sulfohydrolase (SGSH), involved in the catabolism of heparan sulfate. The clinical spectrum is broad and the age of symptom onset and the degree of preservation of cognitive and motor functions appears greatly influenced by genotype. To explore this further, we generated a conditional knockout (SgshKO) mouse model with ubiquitous Sgsh deletion, and compared the clinical and pathological phenotype with that of the spontaneous SgshD31N MPS-IIIA mouse model. Phenotypic deficits were noted in SgshKO mice prior to SgshD31N mice, however these outcomes did not correlate with any shift in the time of appearance nor rate of accumulation of primary (heparan sulfate) or secondary substrates (GM2/GM3 gangliosides). Other disease lesions (elevations in lysosomal integral membrane protein-II expression, reactive astrocytosis and appearance of ubiquitin-positive inclusions) were also comparable between affected mouse strains. This suggests that gross substrate storage and these neuropathological markers are neither primary determinants, nor good biomarkers/indicators of symptom generation, confirming similar observations made recently in MPS-IIIA patients. The SgshKO mouse will be a useful tool for elucidation of the neurological basis of disease and assessment of the clinical efficacy of new treatments for Sanfilippo syndrome.
Glial Fibrillary Acidic Protein Heparan Sulfate Mucopolysaccharidosis Affected Mouse Valstar
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access
This work was supported by the Lysosomal Diseases Research Unit (SAHMRI, Australia). The Monash Gene Targeting Facility was contracted to generate the targeting construct and mice containing the targeted allele. We thank Meghan Setford and Andrew Shoubridge for assistance in genotyping and mouse husbandry; Lynn Garrard and staff at the Women’s and Children’s Health Network Animal Care Facility for care of the mice; Dr. Mark Corbett (Adelaide Neurogenetics Research Group; The University of Adelaide) for providing the CMV-Cre mice, Dr. Mark Adams (Evolutionary Biology Unit, South Australian Museum) for the allozyme electrophoresis and the Australian Genome Research Facility Ltd. for SNP genotyping.
Compliance with ethical standards
Conflicts of interest statement
All institutional and national guidelines for the care and use of laboratory animals were followed.
This article does not contain any studies with human subjects performed by any of the authors.
This work was supported by the Lysosomal Diseases Research Unit (SAHMRI, Australia).
Arfi A, Richard M, Gandolphe C, Bonnefont-Rousselot D, Therond P, Scherman D (2011) Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment. Mol Genet Metab 103:18–25CrossRefPubMedGoogle Scholar
Bhaumik M, Muller VJ, Rozaklis T et al (1999) A mouse model for mucopolysaccharidosis type III a (Sanfilippo syndrome). Glycobiology 9:1389–1396CrossRefPubMedGoogle Scholar
Crawley AC, Gliddon BL, Auclair D et al (2006) Characterization of a C57BL/6 congenic mouse strain of mucopolysaccharidosis type IIIA. Brain Res 1104:1–17CrossRefPubMedGoogle Scholar
Elrick MJ, Pacheco CD, Yu T et al (2010) Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet 19:837–847CrossRefPubMedGoogle Scholar
Fraldi A, Hemsley K, Crawley A et al (2007) Functional correction of CNS lesions in a MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 16:2693–2702CrossRefPubMedGoogle Scholar
Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB (1988) Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 8:2485–2490PubMedGoogle Scholar
Griffey MA, Wozniak D, Wong M et al (2006) CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol Ther 13:538–547CrossRefPubMedGoogle Scholar
Haurigot V, Marco S, Ribera A et al (2013) Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 123:3254–3271CrossRefPubMedCentralGoogle Scholar
Hemsley KM, Beard H, King BM, Hopwood JJ (2008) Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav 7:740–753CrossRefGoogle Scholar
Hemsley KM, Hopwood JJ (2005) Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Behav Brain Res 158:191–199CrossRefPubMedGoogle Scholar
Hemsley KM, Luck AJ, Crawley AC et al (2009) Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci 29:1197–1214CrossRefPubMedGoogle Scholar
Hopwood JJ, Elliott H (1982) Diagnosis of Sanfilippo a syndrome by estimation of sulphamidase activity using a radiolabelled tetrasaccharide substrate. Clin Chim Acta 123:241–250CrossRefPubMedGoogle Scholar
Keating DJ, Winter MA, Hemsley KM et al (2012) Exocytosis is impaired in mucopolysaccharidosis IIIA mouse chromaffin cells. Neuroscience 227:110–118CrossRefPubMedGoogle Scholar
Lau AA, Crawley AC, Hopwood JJ, Hemsley KM (2008) Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Behav Brain Res 91:130–136CrossRefGoogle Scholar
Lau AA, Hopwood JJ, Kremer EJ, Hemsley KM (2010) SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors. Mol Genet Metab 100:168–175CrossRefPubMedGoogle Scholar
Lau AA, Shamsani NJ, Winner LK et al (2013) Neonatal bone marrow transplantation in MPS IIIA mice. JIMD reports 8:121–132CrossRefPubMedGoogle Scholar
Marco S, Pujol A, Roca C, et al (2016) Progressive neurologic and somatic disease in a novel model of human mucopolysaccharidosis type IIIC. Dis Model Mech doi:10.1242/dmm.025171Google Scholar
Marshall NR, Hassiotis S, King B et al (2015) Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Exp Neurol 263:79–90CrossRefPubMedGoogle Scholar
Martins C, Hulkova H, Dridi L et al (2015) Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model. Brain 138:336–355CrossRefPubMedPubMedCentralGoogle Scholar
Matern D, Gavrilov D, Oglesbee D, Raymond K, Rinaldo P, Tortorelli S (2015) Newborn screening for lysosomal storage disorders. Semin Perinatol 39:206–216CrossRefPubMedGoogle Scholar
Russell C (2003) Transgenic expression of human alpha-L-iduronidase in mouse and characterization of the long term pathophysiology of murine alpha-L-iduronidase deficiency. In: Transgenic expression of human alpha-L-iduronidase in mouse and characterization of the long term pathophysiology of murine alpha-L-iduronidase deficiency. University of British Colombia, p 177Google Scholar
Savas PS, Hemsley KM, Hopwood JJ (2004) Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 82:273–285CrossRefPubMedGoogle Scholar
Sergijenko A, Langford-Smith A, Liao AY et al (2013) Myeloid/microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther 21:1938–1949CrossRefPubMedPubMedCentralGoogle Scholar
Shapiro EG, Nestrasil I, Delaney KA et al (2016) A prospective natural history study of mucopolysaccharidosis type IIIA. J Pediatr 170(278–287):e274Google Scholar
Sorrentino NC, D’Orsi L, Sambri I et al (2013) A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO molecular medicine 5:675–690CrossRefPubMedPubMedCentralGoogle Scholar
Trim PJ, Hopwood JJ, Snel MF (2015) Butanolysis derivatization: improved sensitivity in LC-MS/MS quantitation of heparan sulfate in urine from Mucopolysaccharidosis patients. Anal Chem 87:9243–9250CrossRefPubMedGoogle Scholar
Valstar MJ, Marchal JP, Grootenhuis M, Colland V, Wijburg FA (2011) Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome). Orphanet journal of rare diseases 6:43CrossRefPubMedPubMedCentralGoogle Scholar
Valstar MJ, Neijs S, Bruggenwirth HT et al (2010) Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 68:876–887CrossRefPubMedGoogle Scholar
Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA (2008) Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 31:240–252CrossRefPubMedGoogle Scholar
Van Hove JL, Wevers RA, Van Cleemput J et al (2003) Late-onset visceral presentation with cardiomyopathy and without neurological symptoms of adult Sanfilippo a syndrome. Am J Med Genet A 118:382–387CrossRefGoogle Scholar
Villani GR, Gargiulo N, Faraonio R, Castaldo S, Gonzalez YRE, Di Natale P (2007) Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J Neurosci Res 85:612–622CrossRefPubMedGoogle Scholar
Vitry S, Ausseil J, Hocquemiller M, Bigou S, Dos Santos CR, Heard JM (2009) Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB. Mol Cell Neurosci 41:8–18CrossRefPubMedGoogle Scholar
Whyte L, Hopwood J, Hemsley K, Lau A (2015) Variables influencing fluorimetric N-sulfoglucosamine sulfohydrolase (SGSH) activity measurement in brain homogenates. Molecular Genetics and Metabolism Reports 5:60–62CrossRefPubMedPubMedCentralGoogle Scholar